Cargando…

Mixed dementia: A review of the evidence

Mixed dementia is the coexistence of Alzheimer's disease and cerebrovascular disease (CVD) in the same demented patient. Currently, its diagnosis and treatment remains a challenge for practitioners. To provide an overview of the epidemiology, pathogenesis, natural history, diagnosis, and therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Custodio, Nilton, Montesinos, Rosa, Lira, David, Herrera-Pérez, Eder, Bardales, Yadira, Valeriano-Lorenzo, Lucía
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação de Neurologia Cognitiva e do Comportamento 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769994/
https://www.ncbi.nlm.nih.gov/pubmed/29354216
http://dx.doi.org/10.1590/1980-57642016dn11-040005
_version_ 1783293000514797568
author Custodio, Nilton
Montesinos, Rosa
Lira, David
Herrera-Pérez, Eder
Bardales, Yadira
Valeriano-Lorenzo, Lucía
author_facet Custodio, Nilton
Montesinos, Rosa
Lira, David
Herrera-Pérez, Eder
Bardales, Yadira
Valeriano-Lorenzo, Lucía
author_sort Custodio, Nilton
collection PubMed
description Mixed dementia is the coexistence of Alzheimer's disease and cerebrovascular disease (CVD) in the same demented patient. Currently, its diagnosis and treatment remains a challenge for practitioners. To provide an overview of the epidemiology, pathogenesis, natural history, diagnosis, and therapy of Mixed Vascular-Alzheimer Dementia (MVAD). The literature was reviewed for articles published between 1990-2016 by using the keywords linked to MVAD. Neuropathological studies indicate that MVAD is a very common pathological finding in the elderly with a prevalence about of 22%. The distinction between Alzheimer's dementia and vascular dementia (VD) is complex because their clinical presentation can overlap. There are international criteria for the MVAD diagnosis. The pharmacologic therapy shows modest clinical benefits that are similar among all drugs used in patients with Alzheimer's dementia and VD. The non-pharmacologic therapy includes the rigorous management of cardiovascular risk factors (especially hypertension) and the promotion of a healthy diet. The diagnosis and treatment of MVAD cannot be improved without further studies. Currently available medications provide only modest clinical benefits once a patient has developed MVAD. In subjects at risk, the antihypertensive therapy and healthy diet should be recommend for preventing or slowing the progression of MVAD.
format Online
Article
Text
id pubmed-5769994
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Associação de Neurologia Cognitiva e do Comportamento
record_format MEDLINE/PubMed
spelling pubmed-57699942018-01-19 Mixed dementia: A review of the evidence Custodio, Nilton Montesinos, Rosa Lira, David Herrera-Pérez, Eder Bardales, Yadira Valeriano-Lorenzo, Lucía Dement Neuropsychol Views & Reviews Mixed dementia is the coexistence of Alzheimer's disease and cerebrovascular disease (CVD) in the same demented patient. Currently, its diagnosis and treatment remains a challenge for practitioners. To provide an overview of the epidemiology, pathogenesis, natural history, diagnosis, and therapy of Mixed Vascular-Alzheimer Dementia (MVAD). The literature was reviewed for articles published between 1990-2016 by using the keywords linked to MVAD. Neuropathological studies indicate that MVAD is a very common pathological finding in the elderly with a prevalence about of 22%. The distinction between Alzheimer's dementia and vascular dementia (VD) is complex because their clinical presentation can overlap. There are international criteria for the MVAD diagnosis. The pharmacologic therapy shows modest clinical benefits that are similar among all drugs used in patients with Alzheimer's dementia and VD. The non-pharmacologic therapy includes the rigorous management of cardiovascular risk factors (especially hypertension) and the promotion of a healthy diet. The diagnosis and treatment of MVAD cannot be improved without further studies. Currently available medications provide only modest clinical benefits once a patient has developed MVAD. In subjects at risk, the antihypertensive therapy and healthy diet should be recommend for preventing or slowing the progression of MVAD. Associação de Neurologia Cognitiva e do Comportamento 2017 /pmc/articles/PMC5769994/ /pubmed/29354216 http://dx.doi.org/10.1590/1980-57642016dn11-040005 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Views & Reviews
Custodio, Nilton
Montesinos, Rosa
Lira, David
Herrera-Pérez, Eder
Bardales, Yadira
Valeriano-Lorenzo, Lucía
Mixed dementia: A review of the evidence
title Mixed dementia: A review of the evidence
title_full Mixed dementia: A review of the evidence
title_fullStr Mixed dementia: A review of the evidence
title_full_unstemmed Mixed dementia: A review of the evidence
title_short Mixed dementia: A review of the evidence
title_sort mixed dementia: a review of the evidence
topic Views & Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769994/
https://www.ncbi.nlm.nih.gov/pubmed/29354216
http://dx.doi.org/10.1590/1980-57642016dn11-040005
work_keys_str_mv AT custodionilton mixeddementiaareviewoftheevidence
AT montesinosrosa mixeddementiaareviewoftheevidence
AT liradavid mixeddementiaareviewoftheevidence
AT herreraperezeder mixeddementiaareviewoftheevidence
AT bardalesyadira mixeddementiaareviewoftheevidence
AT valerianolorenzolucia mixeddementiaareviewoftheevidence